Cargando…
SARS-CoV-2-specific immune response in COVID-19 convalescent individuals
We collected blood from coronavirus disease 2019 (COVID-19) convalescent individuals and investigated SARS-CoV-2-specific humoral and cellular immunity in these discharged patients. Follow-up analysis in a cohort of 171 patients at 4–11 months after the onset revealed high levels of IgG antibodies....
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261819/ https://www.ncbi.nlm.nih.gov/pubmed/34234102 http://dx.doi.org/10.1038/s41392-021-00686-1 |
_version_ | 1783719077127127040 |
---|---|
author | Pan, Yunbao Jiang, Xianghu Yang, Liu Chen, Liangjun Zeng, Xiaojiao Liu, Guohong Tang, Yueting Qian, Chungen Wang, Xinming Cheng, Fangming Lin, Jun Wang, Xinghuan Li, Yirong |
author_facet | Pan, Yunbao Jiang, Xianghu Yang, Liu Chen, Liangjun Zeng, Xiaojiao Liu, Guohong Tang, Yueting Qian, Chungen Wang, Xinming Cheng, Fangming Lin, Jun Wang, Xinghuan Li, Yirong |
author_sort | Pan, Yunbao |
collection | PubMed |
description | We collected blood from coronavirus disease 2019 (COVID-19) convalescent individuals and investigated SARS-CoV-2-specific humoral and cellular immunity in these discharged patients. Follow-up analysis in a cohort of 171 patients at 4–11 months after the onset revealed high levels of IgG antibodies. A total of 78.1% (164/210) of the specimens tested positive for neutralizing antibody (NAb). SARS-CoV-2 antigen peptide pools-stimulated-IL-2 and -IFN-γ response can distinguish COVID-19 convalescent individuals from healthy donors. Interestingly, NAb survival was significantly affected by the antigen peptide pools-stimulated-IL-2 response, -IL-8 response, and -IFN-γ response. The antigen peptide pools-activated CD8+ T cell counts were correlated with NAb. The antigen peptide pools-activated natural killer (NK) cell counts in convalescent individuals were correlated with NAb and disease severity. Our data suggested that the development of NAb is associated with the activation of T cells and NK cells. Our work provides a basis for further analysis of the protective immunity to SARS-CoV-2 and for understanding the pathogenesis of COVID-19. It also has implications for the development of an effective vaccine for SARS-CoV-2 infection. |
format | Online Article Text |
id | pubmed-8261819 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-82618192021-07-07 SARS-CoV-2-specific immune response in COVID-19 convalescent individuals Pan, Yunbao Jiang, Xianghu Yang, Liu Chen, Liangjun Zeng, Xiaojiao Liu, Guohong Tang, Yueting Qian, Chungen Wang, Xinming Cheng, Fangming Lin, Jun Wang, Xinghuan Li, Yirong Signal Transduct Target Ther Article We collected blood from coronavirus disease 2019 (COVID-19) convalescent individuals and investigated SARS-CoV-2-specific humoral and cellular immunity in these discharged patients. Follow-up analysis in a cohort of 171 patients at 4–11 months after the onset revealed high levels of IgG antibodies. A total of 78.1% (164/210) of the specimens tested positive for neutralizing antibody (NAb). SARS-CoV-2 antigen peptide pools-stimulated-IL-2 and -IFN-γ response can distinguish COVID-19 convalescent individuals from healthy donors. Interestingly, NAb survival was significantly affected by the antigen peptide pools-stimulated-IL-2 response, -IL-8 response, and -IFN-γ response. The antigen peptide pools-activated CD8+ T cell counts were correlated with NAb. The antigen peptide pools-activated natural killer (NK) cell counts in convalescent individuals were correlated with NAb and disease severity. Our data suggested that the development of NAb is associated with the activation of T cells and NK cells. Our work provides a basis for further analysis of the protective immunity to SARS-CoV-2 and for understanding the pathogenesis of COVID-19. It also has implications for the development of an effective vaccine for SARS-CoV-2 infection. Nature Publishing Group UK 2021-07-07 /pmc/articles/PMC8261819/ /pubmed/34234102 http://dx.doi.org/10.1038/s41392-021-00686-1 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Pan, Yunbao Jiang, Xianghu Yang, Liu Chen, Liangjun Zeng, Xiaojiao Liu, Guohong Tang, Yueting Qian, Chungen Wang, Xinming Cheng, Fangming Lin, Jun Wang, Xinghuan Li, Yirong SARS-CoV-2-specific immune response in COVID-19 convalescent individuals |
title | SARS-CoV-2-specific immune response in COVID-19 convalescent individuals |
title_full | SARS-CoV-2-specific immune response in COVID-19 convalescent individuals |
title_fullStr | SARS-CoV-2-specific immune response in COVID-19 convalescent individuals |
title_full_unstemmed | SARS-CoV-2-specific immune response in COVID-19 convalescent individuals |
title_short | SARS-CoV-2-specific immune response in COVID-19 convalescent individuals |
title_sort | sars-cov-2-specific immune response in covid-19 convalescent individuals |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261819/ https://www.ncbi.nlm.nih.gov/pubmed/34234102 http://dx.doi.org/10.1038/s41392-021-00686-1 |
work_keys_str_mv | AT panyunbao sarscov2specificimmuneresponseincovid19convalescentindividuals AT jiangxianghu sarscov2specificimmuneresponseincovid19convalescentindividuals AT yangliu sarscov2specificimmuneresponseincovid19convalescentindividuals AT chenliangjun sarscov2specificimmuneresponseincovid19convalescentindividuals AT zengxiaojiao sarscov2specificimmuneresponseincovid19convalescentindividuals AT liuguohong sarscov2specificimmuneresponseincovid19convalescentindividuals AT tangyueting sarscov2specificimmuneresponseincovid19convalescentindividuals AT qianchungen sarscov2specificimmuneresponseincovid19convalescentindividuals AT wangxinming sarscov2specificimmuneresponseincovid19convalescentindividuals AT chengfangming sarscov2specificimmuneresponseincovid19convalescentindividuals AT linjun sarscov2specificimmuneresponseincovid19convalescentindividuals AT wangxinghuan sarscov2specificimmuneresponseincovid19convalescentindividuals AT liyirong sarscov2specificimmuneresponseincovid19convalescentindividuals |